How should systemic sclerosis be diagnosed and managed, including therapy for skin involvement, interstitial lung disease, Raynaud phenomenon, pulmonary arterial hypertension, renal crisis, and gastrointestinal manifestations?

Systemic Sclerosis: Diagnosis and Treatment

Systemic sclerosis (SSc) should be diagnosed using the 2013 ACR/EULAR classification criteria, with management guided by organ-specific involvement using mycophenolate mofetil, nintedanib, rituximab, and tocilizumab as first-line therapies for skin fibrosis and interstitial lung disease, while employing combination vasodilator therapy for pulmonary arterial hypertension and ACE inhibitors for renal crisis. 1

Diagnosis

SSc diagnosis requires recognition of the characteristic triad: vasculopathy, immune dysregulation with specific autoantibodies, and progressive fibrosis 2. Look specifically for:

• Early clinical features: Raynaud phenomenon (often the first manifestation), hand edema, and fatigue 3
• Autoantibodies: Anticentromere antibodies, anti-topoisomerase I (Scl-70), or anti-RNA polymerase III 2
• Skin involvement pattern: Classify as limited or diffuse cutaneous SSc based on extent of skin thickening
• Mandatory screening: High-resolution CT chest for interstitial lung disease, pulmonary function tests with DLCO, echocardiography for pulmonary arterial hypertension 3, 4

Treatment by Organ Domain

Skin Fibrosis

For progressive skin fibrosis, use mycophenolate mofetil as first-line therapy, with rituximab, tocilizumab, or nintedanib as alternative first-line options 1. This represents a major advance from previous recommendations, as these are the first synthetic and biological targeted therapies specifically recommended for SSc skin involvement.

Interstitial Lung Disease (ILD)

Mycophenolate mofetil is the preferred first-line treatment for SSc-ILD 5, 3. The treatment algorithm is:

• First-line options: Mycophenolate mofetil (preferred), rituximab, cyclophosphamide, or nintedanib 1, 5
• Progressive disease despite first therapy: Consider combination therapy with mycophenolate mofetil plus nintedanib, which shows the best prognostic improvements 4
• Rapidly progressive ILD: Use IV glucocorticoids PLUS one or two additional therapies (rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitor, or JAK inhibitor), with early lung transplant referral 5

Critical caveat: In SSc patients with rapidly progressive ILD, there is no consensus on glucocorticoid use due to renal crisis risk; if used, monitor closely for renal complications 5

Strongly avoid long-term glucocorticoids for SSc-ILD due to lack of efficacy and significant harm 5

Pulmonary Arterial Hypertension (PAH)

Use first-line combination therapy with a phosphodiesterase-5 inhibitor PLUS an endothelin receptor antagonist for newly diagnosed PAH 1, 3. This represents updated guidance prioritizing upfront combination therapy rather than sequential monotherapy. Add selexipag or riociguat for inadequate response 6.

Raynaud Phenomenon

Vasodilator therapy is first-line treatment 3. Use calcium channel blockers (typically nifedipine or amlodipine) as initial therapy 1.

Digital Ulcers

Phosphodiesterase-5 inhibitors and intravenous iloprost are first-line treatments for active digital ulcers 1, 3. Prevention strategies are equally important in patients with recurrent ulcers.

Scleroderma Renal Crisis

ACE inhibitors are the acute treatment of choice and have dramatically reduced mortality from renal crisis since the 1980s 4. This intervention, combined with more cautious corticosteroid use, transformed renal crisis from a common, highly lethal complication to a manageable one.

Key prevention strategy: Avoid or minimize corticosteroid use, particularly doses >15 mg/day, as they increase renal crisis risk 5, 4

Gastrointestinal Manifestations

Management targets specific symptoms 1:

• Reflux/esophageal dysmotility: Proton pump inhibitors
• Bacterial overgrowth: Rotating antibiotics
• Motility disorders: Prokinetic agents (though evidence remains limited) 6

Musculoskeletal Involvement (Arthritis)

Standard immunosuppressive therapies used for skin and lung involvement typically address articular manifestations 1. Consider methotrexate or other DMARDs if arthritis is prominent.

Disease-Modifying Approaches

For carefully selected high-risk patients with rapidly progressive disease, autologous hematopoietic stem cell transplantation offers a proven disease-modifying option 6. This requires specialized center evaluation and carries significant risks but can alter disease trajectory.

Critical Clinical Pitfalls

1. Delayed ILD screening: Pulmonary involvement is now the leading cause of death in SSc, having surpassed renal crisis 4. Use HR-CT screening liberally for early detection.

2. Corticosteroid overuse: While tempting for inflammatory features, glucocorticoids increase renal crisis risk and lack efficacy for fibrotic manifestations 5, 4

3. Sequential monotherapy in PAH: The shift to upfront combination therapy reflects improved survival data 1, 6

4. Undertreatment of progressive disease: Don't hesitate to escalate to combination immunosuppression (e.g., mycophenolate + nintedanib) for progressive ILD 4

Monitoring Strategy

Establish baseline and serial monitoring:

• Every 3-6 months: Pulmonary function tests (FVC, DLCO), echocardiography
• Annually or with symptoms: High-resolution CT chest
• Ongoing: Blood pressure monitoring (for renal crisis detection), skin score assessment

The heterogeneity of SSc demands organ-specific risk stratification using autoantibody profiles (anti-topoisomerase I predicts ILD; anticentromere predicts PAH; anti-RNA polymerase III predicts renal crisis) to guide surveillance intensity 2.